Abstracts tagged "Vasculitis"

Abstract Number: 2918 • 2019 ACR/ARP Annual Meeting
Metabolic Signatures of Pathogenic T Cells in Medium and Large Vessel Vasculitis
Mitsuhiro Akiyama ¹, Hui Zhang ¹, Ryu Watanabe ¹, Toshihisa Maeda ², Gerald Berry ¹, Jorg Goronzy ¹ and Cornelia Weyand¹, ¹Stanford University, Stanford, CA, ²Matsubara Mayflower Hospital, Kobe, Japan
Background/Purpose: Giant cell arteritis (GCA) is an autoimmune vasculitis that causes aortic arch syndrome, blindnesss, and stroke. Embedded in granulomatous infiltrates, CD4 T cells persist…
Abstract Number: 1667 • 2019 ACR/ARP Annual Meeting
Long Term Outcome of Hydralazine-Associated Vasculitis
Saja Almaaitah¹, Kinanah Yaseen ², Yuxuan Jin ³ and Rula Hajj-ali ⁴, ¹Internal Medicine Residency/Cleveland Clinic, University Heights, OH, ²Cleveland Clinic, Cleveland, OH, ³Quantitative Health Science, Cleveland Clinic, Cleveland, OH, ⁴Rheumatologic and Immunologic Disease/Cleveland Clinic, Cleveland, OH
Background/Purpose: Hydralazine associated vasculitis (HAV) is rare but with potentially detrimental complications, affecting different organ systems. Most case series described short term disease course. Hence,…
Abstract Number: 1747 • 2019 ACR/ARP Annual Meeting
Practice Variations in Treatment of Pediatric Anti-neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (AAV) with Renal Disease
Audrea Chen¹, Cherry Mammen ¹, Jaime Guzman ², David Cabral ² and Kimberly Morishita ¹, ¹BC Children's Hospital, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Renal disease is common in ANCA-associated vasculitis (AAV) and one of the goals of early treatment is to maximize renal function recovery. Corticosteroids are…
Abstract Number: 1670 • 2019 ACR/ARP Annual Meeting
Evaluation of Subclinical Coronary Atherosclerosis in ANCA-associated Small Vessel Vasculitides (AAVs) Compared to Matched Controls Through Visual Assessment of Coronary Arterial Calcium (CAC) Score Using Non-Gated Chest Computed Tomography (CT)
Sohail Farshad¹, Alexandra Halalau ², Sayf Al-Katib ³, Julie George ⁴ and Elena Schiopu ⁵, ¹Department of Internal Medicine, Beaumont Health System, Royal Oak, MI, ²Department of Internal Medicine, Beaumont Health System, Royal Oak, ³Department of Radiology, Beaumont Health System, Royal Oak, MI, ⁴Beaumont Health System, Royal Oak, MI, ⁵Department of Rheumatology, University of Michigan, Ann Arbor
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is the most prevalent adult vasculitis and is associated with significant inflammatory burden; chest computed tomography (CT)…
Abstract Number: 2104 • 2019 ACR/ARP Annual Meeting
Vasculitis in HIV-Infected Individuals: Making the Case for an Antigen Driven Process
Courtney McCray¹, Gloria Salazar ², Ryan Valicek ¹, Binh Nguyen ³, Benjamin Naovarat ⁴, Francis Williams ² and John Reveille ², ¹University of Texas McGovern Medical School, Houston, TX, ²University of Texas McGovern Medical School, Houston, ³University of Texas McGoven Medical School, Houston, ⁴University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: A large spectrum of vasculitides affecting small, medium, and large vessels have been reported in HIV-infected individuals. Although vasculitis is a rare manifestation of…
Abstract Number: 1671 • 2019 ACR/ARP Annual Meeting
Hospital Admissions and Mortality in Patients with ANCA-associated Vasculitis
Jon Golenbiewski¹, Amanda Eudy ², Megan Clowse ² and Nancy Allen ², ¹Duke University, Durham, NC, ²Duke University, Durham
Background/Purpose: ANCA-associated vasculitis (AAV) has a high rate of complications, both from disease itself and treatments. Hospital mortality rates for AAV range between 10-20%. There…
Abstract Number: 2281 • 2019 ACR/ARP Annual Meeting
The Vasculitis Pregnancy Registry (V-PREG): Information from the First 3 Years
Jon Golenbiewski¹, Kalen Young ², Cristina Burroughs ³, Joyce Kullman ², Peter Merkel ⁴ and Megan Clowse ⁵, ¹Duke University Medical Center, Durham, NC, ²Vasculitis Foundation, Kansas City, MO, ³University of South Florida, Tampa, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Duke University, Durham
Background/Purpose: As outcomes for patients with vasculitis improve and treatments become less ovarian-toxic, more women with these diseases will become pregnant. How best to manage…
Abstract Number: 1675 • 2019 ACR/ARP Annual Meeting
A Retrospective Cohort Study Using Clinical Notes and Latent Topic Modeling to Characterize the Natural History of ANCA-Associated Vasculitis
Liqin Wang¹, Eli Miloslavsky ², John Stone ³, Hyon K. Choi ⁴, Li Zhou ⁵ and Zachary Wallace ², ¹Brigham and Women's Hospital, Boston, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is associated with end-organ damage, complications of treatment, and excess death. Retrospective studies on the clinical course of AAV, including the…
Abstract Number: 2620 • 2019 ACR/ARP Annual Meeting
Effects of Tofacitinib Suppressed Pulmonary Vascular Remodeling of Allergic Vasculitis in a Murine Model
Yuka Oikawa¹, Kohei Yamauchi ² and Makoto Maemondo ¹, ¹Iwate Medical University School of Medicine, Morioka, Japan, Division of Pulmonary medicine, Allergy and Rheumatology, Department of Internal Medicine, morioka, Japan, ²Takizawa central Hospital, morioka, Japan
Background/Purpose: We reported allergic granulomatous vasculitis with eosinophil infiltration in an asthma model of C57BL/6 sensitized with ovalbumin (OVA). TGF-btea and IL-6 are thought to…
Abstract Number: 1677 • 2019 ACR/ARP Annual Meeting
Management of Severe Renal Disease in Anti-Neutrophil-Cytoplasmic-Antibodies Associated Vasculitis: Role of Rituximab and Plasma Exchange?
Pauline Morel ¹, Alexandre Karras ², Raphael Porcher ³, Xavier Belenfant ⁴, Vincent Audard ⁵, Cédric Rafat ⁶, Guillaume Hanouna ⁷, Séverine Beaudreuil ⁸, Cédric Vilain ⁹, Aurélie Hummel ¹⁰, Benjamin Terrier ¹¹, Evangeline Pillebout ¹², Matthieu Groh ¹³, Romain Jouenne ¹⁴, Robin Dhote ¹⁵, Olivier Fain ¹⁶, Matthieu Ponsoye ¹⁷, Nicolas Noel ¹⁸, Nicolas Limal ¹⁹, Loïc Guillevin ¹¹, Luc Mouthon ¹¹ and Alexis Régent¹¹, ¹Cochin Hospital, Paris, France, ²Paris HEGP, Paris, France, ³Hotel Dieu Hospital, Paris, France, ⁴Service de néphrologie, Hôpital André Grégoire, 56 Boulevard de la Boissière Montreuil, France, Montreuil, Ile-de-France, France, ⁵Henri Mondor Hospital, Créteil, France, ⁶Tenon Hospital, Paris, France, ⁷Service de néphrologie, Hôpital Bichat-Claude Bernard, AP-HP, 46 rue Henri Huchard, Paris, France., Paris, Ile-de-France, France, ⁸Bicetre Hospital, Le Kremlin Bicetre, France, ⁹Service de néphrologie hémodialyse, Hôpital Ambroise Paré, APHP, 9 avenue Charles de Gaulle, Boulogne-Billancourt, France, Boulogne-Billancourt, Ile-de-France, France, ¹⁰APHP, Paris, France, ¹¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ¹²Service de néphrologie et transplantation, Hôpital Saint-Louis, AP-HP, 1 avenue Claude Vellefaux, Paris, France., Paris, Ile-de-France, France, ¹³Service de médecine interne, maladies systémiques, Hôpital Saint Louis, AP-HP, 1 avenue Claude Vellefaux, Paris, France, Paris, Ile-de-France, France, ¹⁴Service de médecine interne, Hôpital Bichat-Claude Bernard, AP-HP, 46 rue Henri Huchard, Paris, France, Paris, Ile-de-France, France, ¹⁵Service de médecine interne, Hôpital Avicenne, AP-PH, 125 rue de Stalingrad, Bobigny, France, Bobigny, Ile-de-France, France, ¹⁶Service de médecine interne, Hôpital Saint-Antoine, AP-HP, 184 rue du Faubourg Saint-Antoine, Paris, France, Paris, Ile-de-France, France, ¹⁷Service de médecine interne, Hopital Ambroise Paré, Boulogne-Billancourt, Boulogne-Billancourt, Ile-de-France, France, ¹⁸Service de médecine interne et immunologie clinique, Hôpital Bicêtre, AP-HP, 78 rue du Général Leclerc, Kremlin-Bicêtre, France, Kremil-Bicêtre, Ile-de-France, France, ¹⁹Service de médecine interne, Hôpital Henri-Mondor, AP-HP, 51 Avenue du Maréchal de Lattre de Tassigny, Créteil, France, Créteil, Ile-de-France, France
Background/Purpose: Induction therapy for severe ANCA-associated vasculitides (AAVs) is based on the combination of glucocorticoids and cyclophosphamide (CYC) or rituximab (RTX). For patients with severe…
Abstract Number: 2621 • 2019 ACR/ARP Annual Meeting
Association Between Outcome Renal, Clinical Variables and Findings of Renal Biopsy in Patients with ANCA Vasculitis
Linda Vergel Orduz¹, Alejandro Brigante ², Diego Marino ³, Natalia Perrotta ³, Romina Hassan ⁴, Gisele Verna ⁵, Adriana Hamaui ⁶, Eduardo Kerzberg ⁷ and Diana Dubinsky ⁶, ¹Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, ²Sanatorio Güemes, Servicio de Medicina Interna – Reumatología, Francisco Acuña de Figueroa 1240, C1180AAD, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ³Hospital de Clínicas José de San Martín, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Hospital Ramos Mejía, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁵Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁶Sanatorio Güemes, Buenos Aires, Argentina, ⁷Hospital Ramos Mejia, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: In associated ANCA vasculitis (AAV), rapidly progressive glomerulonephritis (GN) is one of the most serious complications. In 40% of cases they progress to chronic…
Abstract Number: 312 • 2019 ACR/ARP Annual Meeting
Timely Glucocorticoid Tapering in Vasculitis: A Need for Improved Knowledge Translation to Limit Toxicity
Arielle Mendel¹, Daniel Ennis ², Shirley Lake ³, Simon Carette ⁴ and Christian Pagnoux ⁴, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Sunnybrook Hospital, Toronto, ON, Canada, ⁴Mount Sinai Hospital and University Health Network, Toronto, ON, Canada
Background/Purpose: High dose glucocorticoids (GC) are part of the initial treatment of ANCA-associated (AAV) and large vessel vasculitides (LVV). Prompt subsequent tapering limits toxicity. Adherence…
Abstract Number: 1679 • 2019 ACR/ARP Annual Meeting
Adaptive Study Design of a Randomized, Multicenter, 2-Part Phase 2 Trial of Replacement of Glucocorticoids by IFX-1, a C5a Inhibitor, in Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Peter Merkel¹, Bernhard Hellmich ², David Jayne ³, Simon Rückinger ⁴, Zsuzsanna Tamas ⁵, Claus Thielert ⁵ and Othmar Zenker ⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, Kirchheim, Germany, ³Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ⁴Metronomia Clinical Research GmbH, Munich, Germany, ⁵InflaRx GmbH, Planegg, Germany, ⁶InflaRx GmbH, Jena, Germany
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are life-threatening rare autoimmune diseases are both forms of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Standard of…
Abstract Number: 2627 • 2019 ACR/ARP Annual Meeting
Association of Work Productivity Assessed by Absenteeism and Presenteeism with Disease Activity, Damage and Health-related Quality of Life in Patients with ANCA-associated Vasculitis
Shinya Hirahara¹, Yasuhiro Katsumata ¹, Ken-ei Sada ², Hiroko Nagafuchi ³, Eiichi Tanaka ¹ and Masayoshi Harigai ¹, ¹Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Kitaku, Okayama, Japan, ³Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan
Background/Purpose: Chronic inflammatory diseases such as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) substantially affects patients’ daily lives, including their ability to work. Although the management…
Abstract Number: 806 • 2019 ACR/ARP Annual Meeting
A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease
Rona Smith¹, David Jayne ² and Peter Merkel ³, ¹University of Cambridge, Cambridge, England, United Kingdom, ²Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ³University of Pennsylvania, Philadelphia
Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and relapse rates…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].